The pharma company said it would lay off a third of its workforce and add a black-box warning to its controversial gene ...

The company will pause several gene therapy development programs, for which it intends to seek partners and other strategic alternatives.

Sarepta Therapeutics appears to have right-sized itself after laying off over a third of its staff, announcing a significant ...

Sarepta stock catapulted Thursday after the company announced a restructuring that includes 500 layoffs in the wake of two patient deaths.

Sarepta Therapeutics Inc. is cutting more than one-third of its workforce and will add a black box warning label to its gene therapy for a fatal muscle disorder after two patient deaths raised doubts ...

The company aims to focus on high-impact programmes to meet its 2027 financial obligations and support long-term viability.

The favorable market reaction indicates investor relief at management’s swift measures to rectify the company's worsening ...

Sarepta's cost-saving moves, FDA surprises, and pipeline potential position SRPT as a unique opportunity. Read here for an ...

New research has identified the enzyme glutamate dehydrogenase 1 (GLUD1) as a new therapeutic target for Duchenne muscular ...

Sarepta Therapeutics said it will eliminate 36% of its workforce—approximately 500 jobs—in a restructuring that follows the ...

The drastic cost-cutting move follows the deaths of two teenagers that forced the company to restrict usage of its gene ...

The company will also add a warning label to its drug Elevidys after the deaths of two teenage patients this year.